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mine is an anticholinesterase and usually used for 
reversal of the residual neuromuscular blockade. It is 
well known that neostigmine induces bradycardia by 
inhibiting hydrolysis of acetylcholine released by para-
sympathetic neurons regulating the heart 2）. It has 
been suggested that reversal of the neuromuscular 
blockade by neostigmine produces serious complica-
tion such as cardiac arrest due to its cholinergic 
effect 3,4）. To avoid such serious adverse effects, atro-
pine should be routinely administrated together with 
neostigmine for reversal of the neuromuscular block-
ade.
INTRODUCTION
Several anesthesia-related drugs are associated 
with life-threatening cardiovascular events. Particular-
ly, anticholinesterase, one of reversal of neuromuscular 
blockades may cause bradycardia and bradyarrthyth-
mias such as junctional rhythm or asystole 1）. Neostig-
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ABSTRACT
Dispersion of QT dispersion（QTD）in 12-lead electrocardiogram is a useful index for assessment of ven-
tricular arrhythmia risk and cardiovascular event. To determine the effects of reversal of nondepolarizing 
neuromuscular blockade on cardiovascular event, we evaluated the QT interval QTD after reversal of the 
neuromuscular blockade by neostigmine or sugammadex.
After obtaining the approval of the ethics committee of Dokkyo Medical University Hospital, 40 patients 
with ASA physical status I or II were allocated to following two groups. Patients in the groups N（n＝16）
and S（n＝15）received combination of neostigmine（40 µg/kg）and atropine（20 µg/kg）or sugammadex
（2 mg/kg）as a reversal of neuromuscular blockade after the operation under 1％ sevoflurane anesthesia, 
respectively. The RR interval, QT interval（QT）, corrected QT interval（QTc）, QT dispersion and correct-
ed QT dispersion（QTcD）were consecutively recorded using computerized measurement before and after 
administration of reversal agents in both groups.
RR interval in the group N significantly decreased 1-4 min after reversal of the neuromuscular blockade, 
but not in the group S. However, in the groups N and S, QT interval, QTc interval, QTD and QTcD were 
not changed after reversal of the neuromuscular blockade. Moreover, there was no significant difference 
between both groups in QT interval, QTc interval, QTD and QTcD during the study.
Our results suggest that neither neostigmine nor sugammadex may increase the risk of ventricular 
arrhythmia and cardiovascular events in reversal of the neuromuscular blockade under sevoflurane anes-
thesia.
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QT interval prolongation caused by anesthetics and 
opioids is also another problem during anesthesia 
because of a risk of torsades de pointes 5,6）. The previ-
ous study revealed that neostigmine may produce 
prolongation of rate- corrected QT（QTc）interval on 
electrocardiogram1）. In contrast, it has been reported 
that neostigmine with anticholinergic agent has no 
effect on QTc interval during anesthesia 7）.
Sugammadex, a selective relaxant binding agent 
which is a modified g-cyclodextrin compound, revers-
es the effect of steroidal nondepolarising neuromuscu-
lar blocking agents , rocuronium bromide and 
vecuronium bromide by immediate encapsulation7〜9）. 
Sugammadex is used for complete and rapid reversal 
for moderate or deep muscle relaxant 6 ,10）. Since 
sugammadex does not block acetylcholinesterase 
unlike neostigmine, co-administration of anticholiner-
gic agent is not required 6）. Moreover, it has been 
demonstrated that 4 mg/kg sugammadex did not pro-
long QTc interval under the propofol or sevoflurane 
anesthesia 7）. Sugammadex is thought to have fewer 
adverse cardiovascular effects, compared to neostig-
mine.
Dispersion of QT interval（QTD）is defined as maxi-
mal QT interval minus minimal QT interval on 
12-lead of the surface electrocardiogram（ECG）
reflects regional heterogeneity of ventricular repolar-
ization 11）, and is significantly greater in patient with 
ventricular arrhythmia than in those without 12〜14）. 
QTD is also considered as an important predictor of a 
serious cardiac event such as ventricular arrhythmia. 
Our previous study suggested that tracheal intubation 
is associated with a risk for increase of QTD15）. In our 
study, the increase in QTD during tracheal intubation 
was prevented by landiolol, which is an ultra- short 
acting b1-adrenoceptor antagonist.
Although adverse effects of neostigimine on the car-
diovascular system including QT interval prolongation 
are well known, the effect of reversal of the neuro-
muscular blockade on QTD has not been assessed. 
The purpose of this study is to determine the effects 
of neostigmine and sugammadex on RR interval, QT 
interval, rate-corrected QT（QTc）interval, QTD and 
rate-corrected QTD（QTcD）using computerized mea-
surement.
METHODS
After obtaining the approval of the ethic committee 
of Dokkyo Medical University and written informed 
consent for each patient, 40 patients with ASA physi-
cal status I or II aged 20-60 years who were sched-
uled to undergo elective otorhinolaryngological sur-
gery were studied. They were 15％ of ideal body 
weight. All patients with cardiovascular respiratory, 
metabolic or cerebrovascular disease were excluded 
from this study. Patients with predicted difficulty in 
tracheal intubation were also excluded. No patient 
received any medication. No premedication was given 
to any patients. Patients were randomly allocated fol-
lowing two groups：patients in the groups N（n＝16）
and S（n＝15）received combination of neostigmine
（40 µg/kg）and atropine（20 µg/kg）or sugammadex
（2 mg/kg）as reversal of neuromuscular blockade 
after the operation under 1％ sevoflurane anesthesia, 
respectively.
After patient arrival at the operation room, stan-
dard 12- lead ECGs（FDX-4521L；Fukuda Denshi 
Co. Ltd., Tokyo, Japan）, noninvasive arterial blood 
pressure, pulse oximetry were monitored. After pre-
oxygenation with 100％ oxygen, anesthesia was 
induced with IV propofol 1.5 mg/kg, rocuronium 0.6 
mg/kg and remifentanil 0.2 µg/kg/min. During mask 
ventilation, 2％ sevoflurane with 100％ oxygen was 
added. Tracheal intubation was performed by an 
experienced anesthesiologist who was accomplished 
within 20 seconds. Anesthesia was maintained with 
remifentanil（0.2-0.3 µg/kg/min）, air- oxygen mixture 
and sevoflurane（1-1.5％）. The ventilator was adjust-
ed to end-tidal carbon dioxide tension（PETCO2）was 
35-40 mmHg during the study. All patents received a 
continuous infusion of acetate Ringer’s solution at a 
rate of 5 mg/kg/h during the study. No additional 
rocuronium was given during the maintenance of 
anesthesia.
At the end of surgery, remifentanil was stopped, 
and then 12-lead ECG was measured under 1％ sevo-
flurane. Six minutes after the end of operation, neo-
stigmine or sugammadex was administrated as rever-
sal of the neuromuscular blockade. Measurement of 
RR interval, QT interval, QTc interval, QTD and 
QTcD were performed at every minute from the end 
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of surgery to 10 minutes after reversal of the neuro-
muscular blockade.
From the ECG consecutive beat- to- beat data 
were digitally recorded at a sample rate of two- milli-
seconds. QT intervals were determined by QTD-1
（Fukuda Denshi Co. Ltd.）, which detected the onset 
of the Q wave and the end of the T wave. This tech-
nique determines the onset of the Q wave as the 
intersection of a threshold level with the differential of 
the Q wave, and the end of the T wave as the inter-
section of a threshold level with the differential of the 
T wave, respectively. The software used the differen-
tial threshold technique has been previously described 
in detail 16,17）. QT intervals were measured in all 12 
leads and corrected for heart rate by Bazett’s formula. 
QTD was defined as the difference between the maxi-
mum and minimum average QT interval in 12 lead 
ECG. Similarly, QTcD was defined as the difference 
between the maximum and minimum average QTc 
interval. The average value of data- derived from 
three successive beats for each lead was used for 
analysis. Leads in which the end of the T wave could 
not be clearly detected were excluded from this 
study.
Data are presented as mean±SD. Intergroup differ-
ences were analyzed by two-way analysis of variance
（ANOVA）for the repeated-measures design. When a 
significant overall effect was detected, Tukey’s post 
Table　Demographic data
Group S
（n＝15）
Group N
（n＝16）
Gender（male/female） 9/6 10/6
Age（yrs） 54±15 51±15
Height（cm） 163±8　 166±8　
Weight（kg） 66±18 68±15
There is no significant difference between both groups.
The group S：Sugammadex was administered after the surgery.
The group N：Neostigmine was administered together with 
atropine after the surgery.
Figure 1
Changes in RR interval. ●：the group N, ○：the group S. All values 
are expressed as means±SD. ＊p＜0.05 vs 5 minutes before reversal 
of the neuromuscular blockade. †p＜0.05 vs the group S.
RR interval significantly decreased after reversal of the neuromuscular 
blockade in the group N, but not in the group S.
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hoc test was conducted for comparison of the mean 
values for the two variables. In all analyses, probabili-
ty to detect the difference was set at the 5％ level（P
＜0.05）.
RESULTS
There were no significant differences in age, gender, 
height, or body weight between two groups（Table）. 
No complication was observed throughout this study. 
There is no patient who has abnormalities of RR 
interval, QT interval, QTc interval, QT dispersion and 
QTc dispersion in both groups.
Figure 1 shows the changes in the RR interval 
before and after reversal of the neuromuscular block-
Figure 2
Changes in QT interval. ●：the group N, ○：the group S. All values 
are expressed as means±SD.
There is no significant change in QT interval during the study in 
both groups.
Figure 3
Changes in rate-corrected QT（QTc）interval. ●：the group N, ○：
the group S. All values are expressed as means±SD.
There is no significant change in QTc interval during the study in 
both groups.
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ade in both groups. The RR interval in the group N 
was significantly decreased from 1 to 4 min after 
administration of neostigmine and atropine compared 
with baseline（baseline：978±133 msec, 2 min after 
administration of neostigmine：830±134 msec, P＜
0.05）. Furthermore, the RR interval in the group N 
was significantly lower than that in the group S dur-
ing 1 to 4 min after reversal of the neuromuscular 
blockade（the group N：830±134 msec, the group S：
1005±166 msec, 2 min after reversal of the neuromus-
cular blockade, respectively, p＜0.05）
Both QT and QTc intervals did not have any 
changes after reversal of the neuromuscular blockade 
in the groups N and S（Figure 2 and 3）. Furthermore, 
Figure 4
Changes in QT dispersion. ●：the group N, ○：the group S. All val-
ues are expressed as means±SD.
There is no significant change in QT dispersion interval during the 
study in both groups.
Figure 5
Changes in rate-corrected QTc dispersion（QTcD）. ●：the group N, 
○：the group S. All values are expressed as means±SD.
There is no significant change in QTcD during the study in both 
groups.
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there was no significant difference in both QT and 
QTc intervals between the groups N and S during the 
study.
QTD and QTcD also did not have any changes 
after reversal of the neuromuscular blockade in the 
group N and S（Figure 4 and 5）. Furthermore, there 
was no significant difference in both QTD and QTcD 
between the groups N and S during the study.
DISCUSSION
Sugammadex is the first selective relaxant binding 
agent to reverse the neuromuscular blockade in a dif-
ferent manner from other agents such as neostigmine 
or edrophonium. Sugammadex encapsulates and inac-
tivates nondepolarizing neuromuscular blockade by 
preventing them to bind to acetylcholine receptor at 
the neuromuscular junction 18,19）. This agent is recom-
mended for reversal of moderate or deep muscle 
relaxation induced by rocuronium and vecuronium. 
Although the efficacy and safety of sugammadex has 
been established, it has several problems for clinical 
use, such as anaphylactic shock, cost, and others.
It has been reported that supra-therapeutic or ther-
apeutic doses of sugammadex is not associated with 
QTc prolongation during anesthesia 7,20〜22）. In contrast, 
sugamadex under 1.5 minimum alveolar concentration
（MAC）sevoflurane affected to QTc interval, but not 
under propofol anesthesia 23）. In the present study, QT 
and QTc intervals were not prolonged by therapeutic 
use of sugammadex（4 mg/kg）under 1％ sevoflurane 
anesthesia. We hypothesized that these differences 
arose from the depth of sevoflurane anesthesia. Gener-
ally, inhaled anesthetics such as sevoflurane or isoflu-
rane may dose-dependently produce QTc interval 
prolongation 22）. Thus, lower level of inhaled anesthetic 
is likely to have less adverse effect on QT interval.
Neostigmine may produce cardiovascular effects 
such as bradyarrythmia. To prevent the effect of anti-
cholinesterase, anticholinergic, such as atropine is 
commonly added for reversal of the neuromuscular 
blockade. It is well known that QT interval prolonga-
tion is induced by an imbalance in the cardiac sympa-
thetic tone 24）. Such an imbalance is also observed by 
using of anticholinesterase- anticholinergic combina-
tion 1）. This combination may affect the sympathetic 
tone, resulted in QT interval prolongation. Previous 
study suggested that neostigmine produces transient 
QTc interval prolongation during a few minutes after 
the administration 1）. Our hypothesis was that the 
combination of neostigmine and atropine might have 
effect on QTc or QTcD. As it is, the combination of 
neostigmine and atropine decreased RR interval from 
1 min to 4 min after administration, whereas QT and 
QTc interval were unaffected in the present study. 
These results may be supported by the findings 
which QTc interval was not prolonged by neostigmine 
with glycopyrrolate under propofol anesthesia 21）. How-
ever, neostigmine is likely to prolong QTc interval 
under higher concentration of sevoflurane anesthesia.
Similar to neostigmine, sugammadex did not affect 
QT and QTc intervals in the present study. It is easy 
to explain these results, because there are not any 
cholinergic effects and it is not necessary to do co-
administration with any anticholinergics in case of 
sugammadex
The variability of the QT interval in ECG which is 
defined as dispersion of QT reflects regional differenc-
es in ventricular repolarization 11）. Therefore, increased 
QTD has been shown to predispose to ventricular 
arrhythmias. It has been suggested that QTD increase 
in patients with myocardial infarction 14,25,26）, subarach-
noid hemorrhage 27）or diabetes mellitus 28）. de Bruyne 
et al. emphasized that QTD is considered as a predic-
tor of cardiac mortality in elderly men and women12）. 
Although the effects of neostigmine and sugammadex 
on QTc have been established, the effect on QTD and 
QTcD has not been assessed and cleared. This is the 
first study for the assessment of the effects of sugam-
madex and neostigmine on QTD and QTcD. Our 
results indicated that both sugammadex and neostig-
mine have no effect on QTD and QTcD under 1％ 
sevoflurane anesthesia. Hence, the effect of reversal of 
the neuromuscular blockade on QTD can be excluded 
in this case.
In the present study, there is a limitation to evalu-
ate the cardiovascular risk of reversal of the neuro-
muscular blockade. These results were observed 
under 1％ sevoflurane anesthesia. In a clinical situa-
tion, reversal of the neuromuscular blockade is usually 
performed under many different conditions, such as 
light sevoflurane anesthesia, propofol anesthesia, 
awake condition and others. Therefore, assessments 
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the effects of sugammadex and neostigmine on QTD 
under other conditions are essential. Further studies 
under other conditions are required to conclude the 
effect of these agents on QTD.
We conclude that sugammadex and neostigmine at 
therapeutic doses have no effect on QT interval and 
QTD under 1％ sevoflurane anesthesia. Our findings 
may reflect that the possibility of increased risk of 
ventricular arrhythmias is equivalent between sugam-
madex and neostigmine.
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